News

New programs added in respiratory and cardio-metabolic diseases.

Companies announce a collaboration agreement to develop In Situ Hybridization (ISH) protocols for RNA and DNA targets in tissue using reagents provided by Vitro on Lunaphore’s rapid autostaining platform.

Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.

WuXi Biologics' first overseas site in Asia.

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.

A method to activate targeted drugs, or smart drugs, only at the selected site of action, an approach that improves the drug’s therapeutic effect and minimizes side effects, has been developed in a study led by Georgia State University.

XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.

Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.

Save the date for the UK’s only lab-dedicated exhibition showcase!